Autochthonous Case of Rickettsia slovaca Infection in Russia

Ruslan F. Sayfullin, Nadezhda E. Perekopskaya, Ludmila S. Karan, Nadezhda N. Zvereva, Muhammad A. Sayfullin

Author affiliations: Municipal Clinical Hospital No 52, Moscow, Russia (R.F. Sayfullin); Pirogov Russian National Research Medical University, Moscow (R.F. Sayfullin, N.N. Zvereva, M.A. Sayfullin); Infectious Clinical Hospital No. 1, Moscow (N.E. Perekopskaya); Central Scientific Research Institute of Epidemiology, Moscow (L.S. Karan); Gamaleya Institute of Epidemiology and Microbiology, Moscow (M.A. Sayfullin).

DOI: https://doi.org/10.3201/eid2710.204621

We describe an autochthonous case of Rickettsia slovaca infection in a man 35 years of age from Russia who had tickborne lymphadenopathy. We used ELISA and quantitative PCR testing to further identify DNA and confirm diagnosis. Physicians in Russia should consider similar diseases in differential diagnoses after tick bites.

Rickettsia slovaca was isolated in Dermacentor marginatus ticks in 1968 in Slovakia and recognized as a Rickettsia species with unknown pathogenicity. In 1997, a study described the first laboratory-confirmed case of Rickettsia slovaca infection in a human (1). R. slovaca has been detected in 4 of 85 regions of Russia (Figure), and 1 imported case of R. slovaca infection was reported (4–7). The aim of our study was to describe an autochthonous case of R. slovaca infection in a man in Russia.

In May 2019, a 35-year-old male resident of Russia with an unremarkable medical history sought treatment for eschar on the skin of his right shin, painful and enlarged inguinal lymph nodes, rash, pain in his right knee, and severe fatigue. Before onset, he was in a rural village in the Voronezh region of Russia for 8 days, where he had contact with domestic animals and later noticed an insect bite near the location of the eschar. He reported no history of foreign travel in the previous 6 months.
Disease onset began with an ulcer, 2–3 cm in diameter, on his right shin. By days 3–4, the ulcer became an eschar, and the patient experienced chills and sweats at night. By days 5–6, chills and sweats remained, and an erythema up to 5 cm in diameter appeared around the eschar. The patient also noticed pain in his right knee, papular rash on his right leg and the right side of his trunk and neck, and enlarged and painful inguinal and axillary lymph nodes. On day 6, he was examined by a surgeon, who suspected a skin infection and initiated amoxicillin (1.5 g/d). On days 7–8, the rash spread to other limbs, lymph nodes in his neck became painful and enlarged, the pain in his right knee worsened, and low-grade fever (37.4°C–37.6°C) developed.

On day 8 after symptom onset, he was hospitalized at Infectious Clinical Hospital No. 1 in Moscow. At admission, he had a black eschar surrounded by erythema on the upper part of his right shin and vesiculopapular rash on his limbs and trunk concentrated around the eschar and on the skin of the right knee; in addition, there was bright hyperemia of previously existing scratches. Inguinal, axillary, and neck lymph nodes were painful by palpation and enlarged to 1.5–2.0 cm; his right knee was enlarged and painful by palpation and had impaired range of motion. We found no abnormalities from complete blood count and urinalysis on admission. We suspected skin and soft tissue infection with knee arthritis and changed antimicrobial therapy to ceftriaxone (2.0 g/d) and metronidazole (1.5 g/d).

On day 10, his body temperature normalized and the erythema around the eschar faded, but the rash continued to spread (Appendix, https://wwwnc.cdc.gov/EID/article/27/10/20-4621-App1.pdf) and the pain in his knee worsened. He had slightly elevated C-reactive protein (12 mg/L; reference <5 mg/L), but urine and blood cultures showed no growths. Taking into account anamnesis and a black eschar typical of TIBOLA, DEBONEL, and SENLAT syndromes, we suspected rickettsiosis. We detected *Rickettsia* DNA, but only in the sample from the eschar swab sample. We confirmed *R. slovaca* infection by molecular assay on blood and the eschar swab samples, collected on day 10 after disease onset (Appendix). We extracted DNA using a QIAGEN DNeasy blood and tissue kit (https://www.qiagen.com) and tested it with an AmpliSens *Rickettsia* spp. SFG-FL real-time PCR kit (https://www.amplisens.ru). For further confirmation, we used DNA isolated from the swab to sequence partial OmpA (primers Rr190.70p, Rr190.701n) and gltA (primers RpCS.877p, RpCS.1258n) genes (8).

We changed the patient’s antimicrobial therapy to doxycycline (0.2 g/d), and his health improved rapidly. By day 15, pain and edema in his right knee had regressed, the rash had faded, and the eschar had begun to heal. The patient was discharged, but continued taking doxycycline for 10 additional days.

By 2 months after disease onset, the eschar and a few elements of papular rash around it had completely disappeared, but substantial fatigue remained for up to 5 months. For serologic assays, we collected serum samples on days 10, 30, and 160 after disease onset and tested for *Rickettsia* IgM and IgG using a Vircell *Rickettsia conorii* ELISA IgG/IgM kit (https://www.vircell.com). The lack of serologic response that we observed may have been related to the sensitivity of
the ELISA test we used (9). On the basis of our findings, physicians should consider TIBOLA, DEBONEL, and SENLAT syndromes in differential diagnoses after tick bites occurring in Russia.

About the Author
Dr. R.F. Sayfullin is an assistant professor of children’s infectious diseases at the Pirogov Russian National Research Medical University and a pathologist in Municipal Clinical Hospital No. 52 in Moscow, Russia. His research interests include tick-borne infections, tropical diseases, and travel medicine.

References

Equine Herpesvirus 1 Variant and New Marker for Epidemiologic Surveillance, Europe, 2021

Gabrielle Sutton, Camille Normand, Flora Carnet, Anne Couroucé, Marie Garvey, Sophie Castagnet, Christine I. Fortier, Erika S. Hue, Christel Marcillaud-Pitel, Loïc Legrand, Romain Paillot, Pierre-Hugues Pitel, Ann Cullinane, Stéphane Pronost

Author affiliations: University of Caen Normandy, Caen, France (G. Sutton, C. Normand, F. Carnet, A. Couroucé, C.I. Fortier, E.S. Hue, L. Legrand, S. Pronost); LABÉO Frank Duncombe, Saint-Contest, France (G. Sutton, C. Normand, F. Carnet, S. Castagnet, C.I. Fortier, E.S. Hue, L. Legrand, R. Paillot, P.-H. Pitel, S. Pronost); Cisco-Oniris, Nantes, France (A. Couroucé); Irish Equine Centre, Johnstown, Naas, Ireland (M. Garvey, A. Cullinane); Réseau d’Épidémi-Surveillance en Pathologie Equine, Saint-Contest (C. Marcillaud-Pitel, L. Legrand, P.-H. Pitel, S. Pronost); Writtle University College, Chelmsford, UK (R. Paillot)

DOI: https://doi.org/10.3201/eid2710.210704

Equine herpesvirus 1 isolates from a 2021 outbreak of neurologic disease in Europe have a mutation, A713G, in open reading frame 11 not detected in 249 other sequences from equine herpesvirus 1 isolates. This single-nucleotide polymorphism could help identify horses infected with the virus strain linked to this outbreak.

Equine herpesvirus 1 (EHV-1) is a threat to the equine industry, as demonstrated by the ongoing outbreak of neurologic disease initially reported at a large equestrian event in Valencia, Spain. EHV-1 infection is associated with respiratory disease, abortion in mares, neonatal death of foals, ocular disease, and, more rarely, encephalomyelopathy. As of March 26, 2021, a total of 18 horses had died during the outbreak: 11 in Spain, 5 in Germany, and 2 in Belgium. As the horses have returned from Spain to their training yards, the virus has spread to 9 other countries in Europe and to Qatar. EHV-1 is endemic in horse populations worldwide. Reactivation of latent virus can occur at any time, but infected horses are more vulnerable when exposed to stress. When an outbreak occurs during an equestrian event and horses return to their respective countries or regions, the emergence of new cases of EHV-1 in the weeks and months after often elicits questions regarding the involvement of the strain from the original outbreak.
Autochthonous Case of *Rickettsia slovaca* Infection in Russia

Appendix

**Supplementary Methods**

For molecular assay we used samples of EDTA blood (the buffy coat fraction) and the eschar swab samples, all samples was collected on day 10 after disease onset. We collected dry sterile swab from the inoculation eschar as described elsewhere. (1). Before swabbing, we removed a scab from the eschar. The swab was directed toward the base of the eschar at a 50°–60° angle, while being rotated 5–6 times then placed back in the tube and immediately transported to the laboratory. DNA was extracted using a Qiagen DNeasy blood and tissue kit (https://www.qiagen.com) and tested at the Central Research Institute of Epidemiology, Moscow, Russia using an AmpliSens *Rickettsia* spp. real-time PCR kit SFG-FL (https://www.amplisens.ru) according to the manufacturer's instructions and using the internal, negative, and positive controls. The PCR was performed in a Rotor Gene Q real-time PCR cycler (Qiagen).

To identify *Rickettsia* species, we used DNA isolated from the eschar swab to sequence partial OmpA (primers Rr190.70p, Rr190.701n) and gltA (primers RpCS.877p, RpCS.1258n) genes (2). The purified PCR products were sequenced bidirectionally using BigDye Terminator v1.1 Cycle Sequencing kit (Thermo Fisher Scientific, https://www.thermofisher.com) on an Applied Biosystems3500xL Genetic Analyzer (Applied Biosystems, https://www.biosciences.ie). The obtained sequences were deposited in the NCBI GenBank under the accession numbers MT511329 and MT511330. Serum samples for serology assay were collected on days 10, 30, and 160 after the onset of disease and tested for Rickettsia IgM and IgG using the *Rickettsia conorii* ELISA IgG/IgM kit (https://www.vircell.com) according to the manufacturer’s instructions.
References

   https://doi.org/10.3201/eid1710.110332

   https://doi.org/10.1089/vbz.2016.1966

**Appendix Figure.** The patient's eschar, surrounded by a vesicular-papular rash on day 10 after disease onset, before initiating doxycycline.